Curriculum Vitae

Personal information

Sari Tiitinen

Work experience

1. Senior Researcher, Finnish Medicines Agency (FIMEA)
   - 02/2023 - present
   - Quality assessor for biological medicinal products
   - Finland
2. Research and Development Director, Medix Biochemica
   - 03/2019 - 01/2023
   - Responsible for development of antibodies and antigens for in vitro diagnostic (IVD) field
   - Finland
3. Technology Manager in RD, Medix Biochemica
   - 02/2013 - 03/2019
   - Responsible for immunochemical characterization of IVD antibodies
   - Finland
4. Researcher/Project Manager in RD, Finnish Red Cross Blood Service
   - 03/2004 - 01/2013
   - Laboratory researcher and project manager in stem cell glycomics RD projects. Coordinator for biobanking activities.
   - Finland

Education and training

1. Faculty of Medicine, University of Turku
   - 1999 - 2004
   - PhD
   - Bone biology and biomarkers
   - Finland
2. Faculty of Science, University of Oulu
   - 1993 - 1998
   - MSc, biochemistry
   - Biochemistry, molecular biology, monoclonal antibodies
   - Finland

Additional information

Publications

PhD THESIS Alatalo S. Tartrate-resistant acid phosphatase 5b: a serum marker of bone resorption. Turku 2004. ISBN 951-29-2731-4 SCIENTIFIC PUBLICATIONS, Sari Tiitinen (nee Alatalo)

1. Gao J, Ohlmeier S, Nieminen P, Toljamo T, Tiitinen S, et al. Elevated sputum BPIFB1 levels in smokers with chronic obstructive pulmonary disease: a longitudinal study. Am J Physiol Lung Cell Mol Physiol. 2015 Jul 1;309(1):L17_26. doi: 10.1152/ajplung.00082.2015.
2. Hirvonen T, Suila H, Tiitinen S, et al. Production of a recombinant antibody specific for i blood group antigen, a mesenchymal stem cell marker. Biores Open Access. 2013 Oct;2(5):336_45. doi: 10.1089/biores.2013.0026.
3. Hirvonen T, Suila H, Kotovuori A, Ritamo I, Heiskanen A, Sistonen P, Anderson H, Satomaa T, Saarinen J, Tiitinen S, et al. The i blood group antigen as a marker for umbilical cord blood_derived mesenchymal stem cells. Stem Cells Dev. 2012 Feb 10;21(3):455_64. doi: 10.1089/scd.2011.0405.
4. Heiskanen A, Hirvonen T, Salo H, Impola U, Olonen A, Laitinen A, Tiitinen S, et al. Glycomics of bone marrow_derived mesenchymal stem cells can be used to evaluate their cellular differentiation stage. Glycoconj J. 2009 Apr;26(3):367_84. doi: 10.1007/s10719_008_9217_6.
5. Fagerlund KM, Janckila AJ, Ylipahkala H, Tiitinen SL, et al. Clinical performance of six different serum tartrate_resistant acid phosphatase assays for monitoring alendronate treatment. Clin Lab. 2008;54(9_10):347_54.
6. Karhumäki P, Tiitinen SL, Turpeinen H, Parkkinen J. Inhibition of ERK1/2 activation by phenolic antioxidants protects kidney tubular cells during cold storage. Transplantation. 2007 Apr 15;83(7):948_53. doi: 10.1097/01.tp.0000259249.24268.34.
7. Heiskanen A, Satomaa T, Tiitinen S, et al. N_glycolylneuraminic acid xenoantigen contamination of human embryonic and mesenchymal stem cells is substantially reversible. Stem Cells. 2007 Jan;25(1):197_202. doi: 10.1634/stemcells.2006_0444.
8. Salminen EK, Kallioinen MJ, Ala_Houhala MA, Vihinen PP, Tiitinen SL, et al. Survival markers related to bone metastases in prostate cancer. Anticancer Res. 2006 Nov_Dec;26(6C):4879_84.
9. Korpela J, Tiitinen SL, et al. Serum TRACP 5b and ICTP as markers of bone metastases in breast cancer. Anticancer Res. 2006 Jul_Aug;26(4B):3127_32.
10. Fagerlund KM, Ylipahkala H, Tiitinen SL, et al. Effects of proteolysis and reduction on phosphatase and ROS_generating activity of human tartrate_resistant acid phosphatase. Arch Biochem Biophys. 2006 May 15;449(1_2):1_7. doi: 10.1016/j.abb.2006.03.010.
11. Halleen JM, Tiitinen SL, Ylipahkala H, Fagerlund KM, Väänänen HK. Tartrate_resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption. Clin Lab. 2006;52(9_10):499_509.
12. Wang Q, Alén M, Nicholson PH, Halleen JM, Alatalo SL, et al. Differential effects of sex hormones on peri_ and endocortical bone surfaces in pubertal girls. J Clin Endocrinol Metab. 2006 Jan;91(1):277_82. doi: 10.1210/jc.2005_1608.
13. Nenonen A, Cheng S, Ivaska KK, Alatalo SL, et al. Serum TRACP 5b is a useful marker for monitoring

alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res. 2005 Oct;20(10):1804_12. doi: 10.1359/JBMR.050403.
14. Perez_Amodio S, Vogels IM, Schoenmaker T, Jansen DC, Alatalo SL, et al. Endogenous expression and endocytosis of tartrate_resistant acid phosphatase (TRACP) by osteoblast_like cells. Bone. 2005 Jun;36(6):1065_77. doi: 10.1016/j.bone.2005.03.005.
15. Räisänen SR, Alatalo SL, et al. Macrophages overexpressing tartrate_resistant acid phosphatase show altered profile of free radical production and enhanced capacity of bacterial killing. Biochem Biophys Res Commun. 2005 May 27;331(1):120_6. doi: 10.1016/j.bbrc.2005.03.133.
16. Obrant KJ, Ivaska KK, Gerdhem P, Alatalo SL, et al. Biochemical markers of bone turnover are influenced by recently sustained fracture. Bone. 2005 May;36(5):786_92. doi: 10.1016/j.bone.2005.02.009.
17. Janckila AJ, Parthasarathy RN, Parthasarathy LK, Seelan RS, Hsueh YC, Rissanen J, Alatalo SL, Halleen JM, Yam LT. Properties and expression of human tartrate_resistant acid phosphatase isoform 5a by monocyte_derived cells. J Leukoc Biol. 2005 Feb;77(2):209_18. doi: 10.1189/jlb.0504287.
18. Salminen E, Ala_Houhala M, Korpela J, Varpula M, Tiitinen SL, Halleen JM, Väänänen HK. Serum tartrate_resistant acid phosphatase 5b (TRACP 5b) as a marker of skeletal changes in prostate cancer. Acta Oncol. 2005;44(7):742_7. doi: 10.1080/02841860500327586.
19. Kiviranta R, Morko J, Alatalo SL, et al. Impaired bone resorption in cathepsin K_deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio. Bone. 2005 Jan;36(1):159_72. doi: 10.1016/j.bone.2004.09.020.
20. Vääräniemi J, Halleen JM, Kaarlonen K, Ylipahkala H, Alatalo SL, et al. Intracellular machinery for matrix degradation in bone_resorbing osteoclasts. J Bone Miner Res. 2004 Sep;19(9):1432_40. doi: 10.1359/JBMR.040603.
21. Alatalo SL, Ivaska KK, et al. Osteoclast_derived serum tartrate_resistant acid phosphatase 5b in Albers_Schonberg disease (type II autosomal dominant osteopetrosis). Clin Chem. 2004 May;50(5):883_90. doi: 10.1373/clinchem.2003.029355.
22. Gerdhem P, Ivaska KK, Alatalo SL, et al. Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res. 2004 Mar;19(3):386_93. doi: 10.1359/JBMR.0301244.
23. Halleen JM, Räisänen SR, Alatalo SL, Väänänen HK. Potential function for the ROS_generating activity of TRACP. J Bone Miner Res. 2003 Oct;18(10):1908_11. doi: 10.1359/jbmr.2003.18.10.1908.
24. Alatalo SL, Peng Z, et al. A novel immunoassay for the determination of tartrate_resistant acid phosphatase 5b from rat serum. J Bone Miner Res. 2003 Jan;18(1):134_9. doi: 10.1359/jbmr.2003.18.1.134.
25. Halleen JM, Ylipahkala H, Alatalo SL, et al. Serum tartrate_resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density. Calcif Tissue Int. 2002 Jul;71(1):20_5. doi: 10.1007/s00223_001_2122_7.
26. Lindberg MK, Movérare S, Skrtic S, Alatalo S, et al. Two different pathways for the maintenance of trabecular bone in adult male mice. J Bone Miner Res. 2002 Apr;17(4):555_62. doi: 10.1359/jbmr.2002.17.4.555.
27. Kaija H, Alatalo SL, et al. Phosphatase and oxygen radical_generating activities of mammalian purple acid phosphatase are functionally independent. Biochem Biophys Res Commun. 2002 Mar 22;292(1):128_32. doi: 10.1006/bbrc.2002.6615.
28. Lindberg MK, Erlandsson M, Alatalo SL, et al. Estrogen receptor alpha, but not estrogen receptor beta, is involved in the regulation of the OPG/RANKL (osteoprotegerin/receptor activator of NF_kappa B ligand) ratio and serum interleukin_6 in male mice. J Endocrinol. 2001 Dec;171(3):425_33. doi: 10.1677/joe.0.1710425.
29. Surve VV, Andersson N, Alatalo S, et al. Does combined gastrectomy and ovariectomy induce greater osteopenia in young female rats than gastrectomy alone? Calcif Tissue Int. 2001 Nov;69(5):274_80. doi: 10.1007/s002230020044.
30. Lindberg MK, Alatalo SL, et al. Estrogen receptor specificity in the regulation of the skeleton in female mice. J Endocrinol. 2001 Nov;171(2):229_36. doi: 10.1677/joe.0.1710229.
31. Halleen JM, Alatalo SL, et al. Serum tartrate_resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption. Clin Chem. 2001 Mar;47(3):597_600.
32. Alatalo SL, Halleen JM, et al. Rapid screening method for osteoclast differentiation in vitro that measures tartrate_resistant acid phosphatase 5b activity secreted into the culture medium. Clin Chem. 2000 Nov;46(11):1751_4.
33. Halleen JM, Alatalo SL, et al. Tartrate_resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res. 2000 Jul;15(7):1337_45. doi: 10.1359/jbmr.2000.15.7.1337.

Projects

Memberships

Other Relevant Information